My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intra-Cellular Therapies Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Why Mark Minervini may look into INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI)
A fundamental and technical analysis of (NASDAQ:ITCI): Why INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) qualifies as a high growth stock. 
Via Chartmill
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews
 
Via Benzinga
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Shares of Johnson & Johnson (JNJ) sold off on news regarding a dilution of its earnings. The selloff ended when it reach support. 
Via Benzinga
Evaluating INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) using Mark Minervini’s winning stock formula
A fundamental and technical analysis of (NASDAQ:ITCI): Should you consider INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) for high growth investing? 
Via Chartmill
Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy'
Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion 
Via Benzinga
Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
 
Via Benzinga
Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews
 
Via Benzinga
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews
 
Via Benzinga
Nike To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Monday
 
Via Benzinga
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
 
Via Benzinga
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025. 
Via Benzinga
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promising EPS and revenue forecasts. 
Via Benzinga
Top 4 Health Care Stocks You May Want To Dump In Q1
 
Via Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals. 
Via Benzinga
MarketBeat Week in Review – 01/13 - 01/17
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally 
Via MarketBeat
Topics Economy Energy
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive 
Via MarketBeat
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company. 
Via Benzinga
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge
 
Via Benzinga
Nasdaq, S&P 500 Fall As Bond Yields Pressure Tech Stocks
Stocks are a mixed bag to start the week. 
Via Talk Markets
Topics Stocks Stocks / Equities
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
 
Via Benzinga
Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline. 
Via Benzinga
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal
The deal values the smaller biotech company at a 39% premium to last week's closing price. 
Via Investor's Business Daily
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism
ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million... 
Via Stocktwits
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Walgreens Boots Alliance, Aurora Innovation And Delta Air Lines Are Among Top Large Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
Top performers in last week's stock market: Walgreens, Constellation Energy, FTAI Aviation, TD SYNNEX, Aurora Innovation, Royalty Pharma, Micron, Delta Air Lines, Intra-Cellular Therapies, United... 
Via Benzinga
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025. 
Via Benzinga
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk reduction and favorable safety profile. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.